A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
This 2 arm study will compare the efficacy and safety of the standard chemotherapy of the
East German Study Group for Hematology and Oncology versus standard chemotherapy plus
MabThera (375mg/m2 iv, once monthly for 8 cycles) in patients with indolent non-Hodgkin's and
mantle cell lymphoma. The anticipated time on study treatment is 3-12 months, and the target
sample size is 100-500 individuals.